Invests in
Skills
Education
- Uo
- Uo
Lists including Owen
Investments
Work Experience
2018
Partner
2022
Passionate and supportive about biotech, with a focus on early-stage companies. Contact: owen@4biocapital.com | op_smith@icloud.com
Investment Director
2019 - 2022
Principal
2018 - 2019
2024
Director
2024
Director
2023
2023
Director
2023
Cell and Gene Therapy Advisory Committee
2023
2020
Director
2020
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration.
2019
Director
2019
2018 - 2024
Board Member
2018 - 2024
2017 - 2017
Board Observer
2017 - 2017
LogicBio Therapeutics is a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases. The company’s GeneRide technology hitches a therapeutic transgene to a native promoter without disrupting its normal function in the host genome, enabling permanent expression of a functional version of a missing or faulty gene. Thus − with just a single treatment early in a child’s life – LogicBio can potentially deliver a life-long cure for a devastating disease.
2016 - 2017
Board Observer
2016 - 2017
Depixus is developing unique technology to sequence epigenetic modifications to native RNA and DNA at single molecule level.